<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
	<meta http-equiv="content-type" content="text/html; charset=utf-8"/>
	<title></title>
	<meta name="generator" content="LibreOffice 6.0.7.3 (Linux)"/>
	<meta name="author" content="Kuku, Esther"/>
	<meta name="created" content="2022-01-17T15:00:00"/>
	<meta name="changedby" content="Lucking Ian (RQ8) Mid Essex Hospital"/>
	<meta name="changed" content="2022-01-17T15:00:00"/>
	<meta name="AppVersion" content="14.0000"/>
	<meta name="Company" content="BTUH"/>
	<meta name="DocSecurity" content="0"/>
	<meta name="HyperlinksChanged" content="false"/>
	<meta name="LinksUpToDate" content="false"/>
	<meta name="ScaleCrop" content="false"/>
	<meta name="ShareDoc" content="false"/>
	<style type="text/css">
		@page { margin-left: 0.3in; margin-right: 0.39in; margin-top: 0.49in; margin-bottom: 0.49in }
		@page:first { }
		p { margin-bottom: 0.1in; direction: ltr; line-height: 115%; text-align: left; orphans: 2; widows: 2 }
		a:link { color: #0000ff }
	</style>
</head>
<body lang="en-GB" link="#0000ff" dir="ltr">
<div title="header">
	<p style="margin-left: -0.1in; margin-bottom: 0.95in; line-height: 100%">
	<img src="PACC01%20Standard%20Operating%20procedure%20for%20introducing%20prescribing%20and%20supply%20of%20NOACs%20at%20the%20Anticoagulant%20Clinic_html_6498853f064d197c.png" name="Picture 4" align="left" hspace="12" width="794" height="1123" border="0"/>
<br/>

	</p>
</div>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><a name="_GoBack"></a>
<br/>
<br/>

</p>
<table width="735" cellpadding="7" cellspacing="0">
	<col width="134">
	<col width="222">
	<col width="81">
	<col width="109">
	<col width="117">
	<tr valign="top">
		<td width="134" height="22" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Reference: PACC01</b></p>
		</td>
		<td width="222" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Category: Pharmacist Anticoagulant Service</b></p>
		</td>
		<td width="81" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p style="margin-bottom: 0in"><b>Version: </b>
			</p>
			<p align="center"><b>1</b></p>
		</td>
		<td width="109" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p style="margin-bottom: 0in"><b>Date approved</b></p>
			<p><b>15/04/20</b></p>
		</td>
		<td width="117" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p style="margin-right: -0.08in"><b>Review date 30/09/20</b></p>
		</td>
	</tr>
	<tr valign="top">
		<td colspan="2" width="370" height="11" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Approved  by: Dr Paul Cervi</b></p>
		</td>
		<td colspan="3" width="335" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Written by: Amiirah Ropun/Simon Worrall</b></p>
		</td>
	</tr>
	<tr>
		<td colspan="5" width="719" height="11" valign="top" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Target audience: Anticoagulation Pharmacists, Pharmacists
			supporting the anticoagulation clinic during COVID-19 pandemic </b>
			</p>
		</td>
	</tr>
	<tr>
		<td colspan="5" width="719" height="10" valign="top" style="border: 1px solid #000000; padding: 0in 0.08in">
			<p><b>Details of changes</b><b>: New document</b></p>
		</td>
	</tr>
</table>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><font size="4" style="font-size: 16pt"><u><b>Standard
Operating procedure for introducing prescribing and supply of NOACs
at the Anticoagulant Clinic</b></u></font></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Introduction</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Due to the
COVID emergency, it has been agreed by local commissioners and
specialists to review and switch all appropriate patients over to a
NOAC. 
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Purpose</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">The purpose of
the SOP is to provide guidance on the process for identifying
appropriate anticoagulation patients on VKA who need anticoagulant
medicines review and the introduction of NOACs as an alternative
treatment to VKA. The SOP will only include patients with
non-valvular atrial fibrillation and a target INR range of 2 to 3.
Any other indications will be excluded.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Definitions</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<table width="733" cellpadding="7" cellspacing="0">
	<col width="162">
	<col width="540">
	<tr valign="top">
		<td width="162" bgcolor="#d9d9d9" style="background: #d9d9d9" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in"><b>Term</b></p>
		</td>
		<td width="540" bgcolor="#d9d9d9" style="background: #d9d9d9" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in"><b>Explanation</b></p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">NVAF</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">non-valvular atrial fibrillation</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">INR</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">International normalized ratio</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">NOAC</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Non vitamin K antagonist oral
			anticoagulants</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">TTR</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Time in Therapeutic Range</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">VKA</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Vitamin K antagonist</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">ARC</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Anticoagulation review clinic</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">DAWN</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Anticoagulation Software</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">ICE</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Pathology result software</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="162" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">CED</p>
		</td>
		<td width="540" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<p style="margin-right: 0.31in">Electronic clinic letter system</p>
		</td>
	</tr>
</table>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>CONTENTS</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Contents</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">1-Procedure
for Identification of patients 
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Process:</b></u><b>
</b>    
</p>
<ol>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	<u><b>PROCEDURE FOR IDENTIFICATION OF PATIENTS </b></u>
	</p>
</ol>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Anticoagulant
pharmacist will generate list using DAWN, CED, ICE of all patients on
VKA with indications appropriate to switch.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Prioritise in
terms of the following within the AF cohort</p>
<ol>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Patients &gt;70 years of age</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Patients shielding in line with NHS England advice</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Frequent clinic visits (every 7-14 days)</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Patients whom can provide an estimation of recent weight</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Immobile patients requiring domiciliary visits</p>
</ol>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">In terms of
locations, next priorities are 
</p>
<ol start="6">
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Clinic (to minimise repeated site visits )</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Community 
	</p>
</ol>
<p style="margin-left: 0.5in; margin-right: 0.31in; margin-bottom: 0.14in">
<br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Whilst TTR can
be used to prioritise subsequently for switching, TTR will not be a
factor in deciding to exclude / include patients.</p>
<ol>
	<ol>
		<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
		<b>Anticoagulant pharmacist will review list</b></p>
	</ol>
</ol>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Exclude the
following for consideration of switch, these patients are not
eligible for NOACs: 
</p>
<ul>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Hypersensitivity to the active substance or to any of the excipients
		</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Clinically significant active bleeding</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Hepatic disease associated with coagulopathy and clinically relevant
	bleeding risk.</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Lesion or condition, if considered to be a significant risk for
	major bleeding. This may include current or recent gastrointestinal
	ulceration, presence of malignant neoplasms at high risk of
	bleeding, recent brain or spinal injury, recent brain, spinal or
	ophthalmic surgery, recent intracranial haemorrhage, known or
	suspected oesophageal varices, arteriovenous malformations, vascular
	aneurysms or major intraspinal or intracerebral vascular
	abnormalities</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Uncontrolled severe hypertension</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Pregnancy and breast-feeding 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Patients with severe renal impairment – Creatinine clearance
	&lt;15ml/min</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Prosthetic heart valves requiring anticoagulant treatment 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Thrombophilias including antiphospholipid syndrome</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Moderate to severe mitral stenosis</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Active malignancy/chemotherapy (unless advised by a specialist) 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Obesity</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	INR range greater than 2-3</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Prescribed interacting drugs – see individual SPCs 
	</p>
</ul>
<p style="margin-left: 0.5in; margin-bottom: 0.14in">Sources
available include DAWN-AC, Dart, ICE, CED. The reviewing pharmacist
will make a clinical decision (supported by use of risk scoring tools
– see Appendix 1) – if in doubt, consult haematologist.</p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in">Baseline bloods
– see Appendix 2 
</p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in">For patients
with creatinine clearance 15-30ml/min, NOACs can be used, however, a
3 month blood test is recommended after switching, therefore consider
impact on phlebotomy service 
</p>
<ol>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Patient has been deemed eligible for switch to NOAC:</p>
</ol>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<ul>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Contact patient by phone</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	If patient lacks capacity then involve GP/carer 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Gain consent from patient to switch</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Utilise regional decision making tool (<font color="#0000ff"><u><a href="https://midessexccg.nhs.uk/medicines-optimisation/clinical-pathways-and-medication-guidelines/chapter-2-cardiovascular-system-1/3498-af-anticoagulant-clinical-decision-aid-november-2019-v3-0final/file">click
	here</a></u></font>) for excluding patient switch for absolute
	contra-indications only. Risk assess and mitigate any relative
	contra-indications whilst undertaking switch.</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Check bloods (see Appendix 2)</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Confirm patient weight 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Discuss switch reasons and options (see appendix 7) – signpost to
	relevant information sources and supply electronically if required 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Issue prescription for initial hospital supply from pharmacy via JAC
	pharmacy system, unverify prescription on JAC and ensure
	prescription is screened by a second pharmacist</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Issue patient information booklets (found on anticoagulation desk)
	and send with prescription</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Organise courier via dispensary to deliver medicines on the next
	working day at 11am. If this falls on a Saturday, ensure courier is
	available*</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Complete template letter on CED for GP and supply to nominated
	community pharmacy using PharmOutcomes</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Offer patient dedicated helpline to contact if issues (01702 385197)</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Book patient in for 6 week follow up (via telephone consultation)
	with anticoagulant pharmacist. If no issues/concerns then patient
	discharged to GP.</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Inform community nursing teams – contact domiciliary team</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Liaise with anticoagulation pharmacist to update DAWN records and
	deactivate the account 
	</p>
</ul>
<p style="margin-left: 0.5in; margin-right: 0.31in; margin-bottom: 0.14in">
<br/>
<br/>

</p>
<p style="margin-left: 0.5in; margin-right: 0.31in; margin-bottom: 0.14in">
*For switches, a standard 3 day break from warfarin is to be
implemented prior to commencing NOAC</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">       
<u>Patients refusing to review/change anticoagulation therapy:</u> 
</p>
<ul>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	They need to be informed of the significant safety risks associated
	with this and arrange a follow up call dependent on current
	phlebotomy service capacity 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Complete template letter on CED for GP (see Appendix 6)</p>
</ul>
<p style="margin-left: 1in; margin-right: 0.31in; margin-bottom: 0.14in">
<br/>
<br/>

</p>
<p style="margin-left: 0.5in; margin-right: 0.31in; margin-bottom: 0.14in">
<br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><u><b>Appendix</b></u></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 1-
Risk scores calculations</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 2 –
Screening bloods</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 3 -
Bleeding definitions for anticoagulated patients</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 4 -
Pharmacist Training checklist and final sign-off</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 5 –
Template GP letter when patient agrees to switching</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 6 –
Template GP letter when patient declines switching</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Appendix 7 -
Issues to be covered during patient consultation 
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><b>References:</b></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<ol>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Clinical guide for the management of anticoagulant services during
	the coronavirus pandemic, Version 1. NHS England and NHS
	Improvement. Publications approval reference: 001559. 31 March 2020 
	</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Guidance for the Safe Switching of Warfarin to Direct Oral
	Anticoagulants (DOACs) for Patients with Non-Valvular AF and Venous
	Thromboembolism (DVT / PE). Williams H. Royal Pharmaceutical
	Society. 26 March 2020</p>
	<li/>
<p style="margin-right: 0.31in; margin-bottom: 0in; line-height: 100%">
	Atrial Fibrillation Anticoagulant Clinical Decision Aid, Version
	3.0. Adapted from PAC document approved 14<sup>th</sup> January 2019</p>
</ol>
<p style="margin-left: 0.5in; margin-right: 0.31in; margin-bottom: 0.14in; page-break-before: always">
<b>Appendix 1: Risk score definitions</b></p>
<p style="margin-bottom: 0.14in; line-height: 108%"><br/>
<br/>

</p>
<center>
	<table width="542" cellpadding="7" cellspacing="0">
		<col width="20">
		<col width="405">
		<col width="73">
		<tr valign="top">
			<td width="20" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
			<td width="405" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">Definition</p>
			</td>
			<td width="73" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">Score</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">C</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>CCF/HF (diagnosis of, or LVEF &lt; 40% on Echo)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">H</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Hypertension (diagnosis of)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">A<sub>2</sub></p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Age &gt; 75</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">2</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">D</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Diabetes (T1/T2, diagnosis of)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">S<sub>2</sub></p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Previous Stroke/TIA</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">2</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">V</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Vascular disease: Diagnosed IHD, PAD or previous MI</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">A</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Age &gt; 65</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1*</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="20" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">Sc</p>
			</td>
			<td width="405" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Sex category (female)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1**</p>
			</td>
		</tr>
	</table>
</center>
<p align="center" style="margin-bottom: 0.14in; line-height: 108%">*scores
0 if Age&gt;75, as will score 2 under A<sub>2</sub></p>
<p align="center" style="margin-bottom: 0.14in; line-height: 108%">**scores
0 if the patient does not score in any other category</p>
<p style="margin-bottom: 0.14in; line-height: 108%"><br/>
<br/>

</p>
<center>
	<table width="540" cellpadding="7" cellspacing="0">
		<col width="23">
		<col width="401">
		<col width="73">
		<tr valign="top">
			<td width="23" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
			<td width="401" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">Definition</p>
			</td>
			<td width="73" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">Score</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">H</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Hypertension, uncontrolled (SBP&gt;160mmHg)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">A</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Abnormal Renal/Liver function</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1 each</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">S</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Previous stroke</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">B</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Previous bleed (major / CRNM bleed)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">L</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Labile INRs (TTR&lt;60% +/- 2 INRs&gt;5 / 1 INR &gt;8 in
				6months)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">E</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Elderly (&gt;65 years old)</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="23" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">D</p>
			</td>
			<td width="401" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">Drugs: 1 point concurrent NSAID
				+/- antiplatelet. 
				</p>
				<p>1 point for excessive EtOH consumption</p>
			</td>
			<td width="73" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p align="center">1 each</p>
			</td>
		</tr>
	</table>
</center>
<p style="margin-bottom: 0in; line-height: 100%"><br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in; page-break-before: always">
<b>Appendix 2: Screening Bloods</b></p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<ol>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%"><font color="#000000"><b>U&amp;E's&nbsp;</b></font><font color="#000000">–
	Baseline bloods up to 6 months is suitable if Creatinine is within
	normal limits, patient clinically stable and low risk for change
	(consider age, comorbidities, previous AKI, current CKD, diabetes,
	NSAID use and drugs affecting renal function). Beyond this a repeat
	blood test is required. </font>
	</p>
</ol>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<ol start="2">
	<li/>
<p style="margin-bottom: 0in; line-height: 100%"><font color="#000000"><b>LFTs</b></font><font color="#000000">&nbsp;–
	Baseline bloods up to 1 year is suitable. Beyond this a repeat blood
	test is required or new baseline may be needed if suspicion for
	change e.g pre-existing liver or repeated disease, any new
	medications started that may derange LFTs, symptoms not investigated
	that could indicate liver problem.</font></p>
</ol>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in"><font color="#000000"><span lang="en">Patients
with elevated liver enzymes (ALT/AST &gt; 2 x ULN) or total bilirubin
≥ 1.5 x ULN – refer to haematology for further discussion. </span></font>
</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<ol start="3">
	<li/>
<p style="margin-bottom: 0in; line-height: 100%"><font color="#000000"><b>FBC</b></font><font color="#000000">&nbsp;-
	not required blood test unless indicated – i.e. patient presents
	with signs of bleeding </font>
	</p>
</ol>
<ul>
	<ul>
		<li/>
<p style="margin-bottom: 0in; line-height: 100%">If PLT &lt;100
		– GP to monitor every 6 months</p>
		<li/>
<p style="margin-bottom: 0in; line-height: 100%">If PLT &lt;75
		- continue anticoagulation but check CED if known explanation; if
		no explanation /unknown cause refer to haematology</p>
		<li/>
<p style="margin-bottom: 0in; line-height: 100%">If PLT &lt;50
		– anticoagulation contraindicated and refer to haematology if
		this is unexplained 
		</p>
	</ul>
</ul>
<p style="margin-left: 0.5in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<ul>
	<ul>
		<li/>
<p style="margin-bottom: 0in; line-height: 100%">If Hb &lt;100
		– GP to monitor every 6 months</p>
		<li/>
<p style="margin-bottom: 0in; line-height: 100%">If Hb &lt;
		90 - check if already investigated; if not refer to haematology.</p>
	</ul>
</ul>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p align="right" style="margin-bottom: 0.14in"><font color="#000000"><font face="Tahoma, serif"><font size="2" style="font-size: 10pt">Discussed
and approved by Dr Cervi and Terry Dowling – Practice
Pharmacist,Rushbottom Lane Surgery</font></font></font></p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><b>Appendix 3:
Bleeding Definitions for Anticoagulated Patients</b></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in; line-height: 108%">The following
definitions are from the ISTH (International Society of Thrombosis &amp;
Haemostasis) Guidelines 
</p>
<p style="margin-bottom: 0.14in; line-height: 108%"><br/>
<br/>

</p>
<center>
	<table width="667" cellpadding="7" cellspacing="0">
		<col width="139">
		<col width="498">
		<tr valign="top">
			<td width="139" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><b>Term</b></p>
			</td>
			<td width="498" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><b>Definition</b></p>
			</td>
		</tr>
		<tr valign="top">
			<td width="139" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Major Bleed</p>
			</td>
			<td width="498" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">Clinically overt, including any
				one or more of:</p>
				<ol>
					<ol>
						<li/>
<p style="margin-bottom: 0.11in">Bleeding resulting in
						decrease of ≥20g/L Hb in 24hrs</p>
						<li/>
<p style="margin-bottom: 0.11in">Bleeding requiring
						transfusion of ≥2 units RBC</p>
						<li/>
<p style="margin-bottom: 0.11in">Bleeding in critical
						site (intracranial, intraspinal, intraocular, pericardial,
						intra-articular, intramuscular + compartment syndrome,
						retroperitoneal)</p>
						<li/>
<p>Bleeding that leads to death (but see ‘fatal bleed’)</p>
					</ol>
				</ol>
			</td>
		</tr>
		<tr valign="top">
			<td width="139" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">CRNM Bleed 
				</p>
				<p>(Clinically relevant, non-major)</p>
			</td>
			<td width="498" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">Clinically overt bleeding that
				does NOT satisfy any criteria for major bleeding, but leads to
				either:</p>
				<ol>
					<ol>
						<li/>
<p style="margin-bottom: 0.11in">Hospital admission for
						bleeding</p>
						<li/>
<p style="margin-bottom: 0.11in">Physician-guided
						medical/surgical treatment for bleeding</p>
						<li/>
<p> A change in antithrombotic therapy</p>
					</ol>
				</ol>
			</td>
		</tr>
		<tr valign="top">
			<td width="139" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Minor Bleed</p>
			</td>
			<td width="498" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>All clinically overt bleeding not meeting the criteria for
				Major or CRNM Bleeding.</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="139" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Fatal Bleed</p>
			</td>
			<td width="498" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Bleed that <i>directly</i> contributes to death, or is the
				primary cause of death.</p>
			</td>
		</tr>
	</table>
</center>
<p style="margin-bottom: 0.14in; line-height: 108%"> 
</p>
<p style="margin-bottom: 0.14in; line-height: 106%; page-break-before: always">
<b>Appendix 4: Pharmacist Training Checklist &amp; Final Sign-off</b></p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in; line-height: 106%">
<br/>
<br/>

</p>
<dl>
	<dd>
	<table width="616" cellpadding="7" cellspacing="0">
		<col width="143">
		<col width="443">
		<tr>
			<td colspan="2" width="600" valign="top" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>MRC Pharmacist Training Form</p>
			</td>
		</tr>
		<tr>
			<td width="143" height="21" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Pharmacist Name</p>
			</td>
			<td width="443" valign="top" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" width="600" valign="top" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Complete the tasks below in the context of the MRC SOP, using
				all of the training materials specified and any other suitable
				resources required.</p>
			</td>
		</tr>
	</table>
</dl>
<p style="margin-left: 0.5in; margin-bottom: 0.14in; line-height: 106%">
<br/>
<br/>

</p>
<dl>
	<dd>
	<table width="616" cellpadding="7" cellspacing="0">
		<col width="21">
		<col width="430">
		<col width="121">
		<tr valign="top">
			<td colspan="2" width="465" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Task</p>
			</td>
			<td width="121" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Initial &amp; Date completed</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>1</p>
			</td>
			<td width="430" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Familiarise with 2014 NICE AF Guidance</p>
			</td>
			<td width="121" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>2</p>
			</td>
			<td width="430" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Complete SPAF Academy NOAC Masterclass</p>
			</td>
			<td width="121" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>3</p>
			</td>
			<td width="430" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Familiarise with SPARC - Stroke Prevention in AF Risk Tool  
				</p>
			</td>
			<td width="121" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>4</p>
			</td>
			<td width="430" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">Complete CPPE pack :</p>
				<p style="margin-bottom: 0.14in">Advances in anticoagulation</p>
				<p> Atrial fibrillation - Focus on non-vitamin K antagonist oral
				anticoagulants,  Anticoagulation Gateway page (complete modules)</p>
			</td>
			<td width="121" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>5</p>
			</td>
			<td width="430" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Able to describe main points within MMG057 (Use of NOACs in
				NVAF)</p>
			</td>
			<td width="121" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>6</p>
			</td>
			<td width="430" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Read and accurately describe the SOP for introducing
				prescribing and supply of NOACs at the Anticoagulant Clinic</p>
			</td>
			<td width="121" bgcolor="#f2f2f2" style="background: #f2f2f2" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><br/>

				</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="21" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>7</p>
			</td>
			<td width="430" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in">Review and appropriately manage
				4 patients in clinic under supervision (supervisor to sign):</p>
				<ol>
					<ol>
						<li/>
<p style="margin-bottom: 0.11in"></p>
						<li/>
<p style="margin-bottom: 0.11in"></p>
						<li/>
<p style="margin-bottom: 0.11in"></p>
					</ol>
				</ol>
				<p style="margin-left: 0.25in; margin-bottom: 0.11in">4.</p>
				<p style="margin-left: 0.25in"><br/>

				</p>
			</td>
			<td width="121" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p style="margin-bottom: 0.14in"><br/>
<br/>

				</p>
				<p style="margin-bottom: 0.14in"><br/>
<br/>

				</p>
				<p style="margin-bottom: 0.14in"><br/>
<br/>

				</p>
				<p style="margin-bottom: 0.14in"><br/>
<br/>

				</p>
				<p><br/>

				</p>
			</td>
		</tr>
	</table>
</dl>
<p style="margin-left: 0.5in; margin-bottom: 0.14in; line-height: 106%">
<br/>
<br/>

</p>
<dl>
	<dd>
	<table width="616" cellpadding="7" cellspacing="0">
		<col width="143">
		<col width="156">
		<col width="156">
		<col width="103">
		<tr>
			<td colspan="4" width="600" valign="top" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Final Declaration</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" width="600" valign="top" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>I confirm that I have completed the above training in full,
				and that I am able to demonstrate sufficient knowledge &amp;
				understanding to perform the tasks required during the review of
				a patient’s anticoagulant medication in the anticoagulant
				medicine review clinic (MRC) setting</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="143" height="32" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Name</b></font></p>
			</td>
			<td width="156" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Sign</b></font></p>
			</td>
			<td width="156" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Position</b></font></p>
			</td>
			<td width="103" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Date</b></font></p>
			</td>
		</tr>
	</table>
</dl>
<p style="margin-left: 0.5in; margin-bottom: 0.14in; line-height: 106%">
<br/>
<br/>

</p>
<dl>
	<dd>
	<table width="616" cellpadding="7" cellspacing="0">
		<col width="143">
		<col width="156">
		<col width="156">
		<col width="103">
		<tr>
			<td colspan="4" width="600" valign="top" bgcolor="#000000" style="background: #000000" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>Final Sign off (NOAC lead pharmacist or haematology/stroke
				consultant)</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" width="600" valign="top" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p>I have verified that the above-named pharmacist has
				demonstrated sufficient knowledge &amp; understanding to perform
				the tasks required during the review of a patient’s
				anticoagulant medication in the anticoagulant medicine review
				clinic (MRC) setting</p>
			</td>
		</tr>
		<tr valign="top">
			<td width="143" height="32" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Name</b></font></p>
			</td>
			<td width="156" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Sign</b></font></p>
			</td>
			<td width="156" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Position</b></font></p>
			</td>
			<td width="103" style="border: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
				<p><font size="1" style="font-size: 8pt"><b>Date</b></font></p>
			</td>
		</tr>
	</table>
</dl>
<p style="margin-left: 0.5in; margin-bottom: 0in; line-height: 100%"><br/>

</p>
<p style="margin-left: 0.5in; margin-bottom: 0.14in; line-height: 108%">
<br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><b>Appendix 5
– Template GP letter when patient agrees to switching </b>
</p>
<p align="right" style="margin-bottom: 0in; line-height: 100%">The
Anticoagulant clinic (Medicine review Clinic)</p>
<p align="right" style="margin-bottom: 0in; line-height: 100%">Tel
<b>01702 385197</b> (Open 9:00AM to 5:00PM Monday - Friday)<br/>
<br/>

</p>
<p style="margin-bottom: 0in; line-height: 100%">DXXXXX NHS No: XXXX<br/>
<br/>

</p>
<p style="margin-bottom: 0in; line-height: 100%">Dr XXXX</p>
<p style="margin-bottom: 0in; line-height: 100%"><i>ADDRESS</i></p>
<p style="margin-bottom: 0in; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0.14in"><b>Date of telephone consultation:
</b><b>xx/xx/2020</b></p>
<p style="margin-bottom: 0.14in">Dear Dr XXX,</p>
<p style="margin-bottom: 0.14in">It was a pleasure to speak with
PATIENT NAME. Please find below a summary of our discussion.</p>
<p style="margin-bottom: 0.14in"><b>Indication(s) for
anticoagulation</b><u>:</u> XXX</p>
<p style="margin-bottom: 0.14in"><b>Relevant DH</b>: XXX</p>
<p style="margin-bottom: 0.14in"><b>Creatinine Clearance: </b><b>XXX</b></p>
<p style="margin-bottom: 0.14in"><b>Medication changes: Warfarin
stopped , [</b><b>NOAC</b><b>] started.</b></p>
<p style="margin-bottom: 0.14in"><u><b>Patient Information &amp;
Follow up</b></u></p>
<p style="margin-bottom: 0.14in">I have discussed the risks &amp;
benefits of anticoagulation, the potential side-effects and warning
signs that require immediate action. Information leaflets and an
anticoagulant alert card have been provided. The first month’s
treatment has been supplied in clinic.</p>
<p style="margin-bottom: 0.14in">Telephone follow up has been
arranged for 6 weeks’ time to check for any issues with the ongoing
plan (such as compliance and side effects) - I will update you if any
problems arise in the next 6 weeks, otherwise they are discharged
from our service. 
</p>
<p style="margin-bottom: 0.14in"><u><b>GP actions</b></u>: 
</p>
<ol>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%">Please update
	the repeat medication template and continue to supply further 
	</p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%">For guidance
	on long term management of NOAC therapy please see the local
	guidance on the CCG website <font color="#0000ff"><u><a href="https://midessexccg.nhs.uk/medicines-optimisation/clinical-pathways-and-medication-guidelines/chapter-2-cardiovascular-system-1/3498-af-anticoagulant-clinical-decision-aid-november-2019-v3-0final/file">[click
	here]</a></u></font></p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%">Please
	re-check patient weight and blood pressure 
	</p>
</ol>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">Kind regards</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">Anticoagulation Specialist
Pharmacist</p>
<p style="margin-bottom: 0.14in">CC: 
</p>
<p style="margin-bottom: 0.14in">PATIENT NAME</p>
<p style="margin-bottom: 0.14in">ADDRESS</p>
<p style="margin-bottom: 0.14in">Appendix 6 – Template GP letter
when patient declines switching 
</p>
<p align="right" style="margin-bottom: 0in; line-height: 100%">The
Anticoagulant clinic (Medicine review Clinic)</p>
<p align="right" style="margin-bottom: 0in; line-height: 100%">Tel
<b>01702 385197</b> (Open 9:00AM to 5:00PM Monday - Friday)<br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">DXXXXX NHS No: XXXX<br/>
<br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">Dr XXXX</p>
<p style="margin-bottom: 0.14in"><i>ADDRESS</i></p>
<p style="margin-bottom: 0.14in"><b>Date of telephone consultation:
</b><b>xx/xx/2020</b></p>
<p style="margin-bottom: 0.14in">Dear Dr XXX,</p>
<p style="margin-bottom: 0.14in">We have identified this patient as
being suitable to be switched from Warfarin to a NOAC, as the INR
results have been identified as being out of the desired therapeutic
range more than ….% of the time over the last 6 months. We
discussed the benefits and risks of the NOACs with PATIENT NAME,
however the patient declined the switch to a NOAC at this present
time. 
</p>
<p style="margin-bottom: 0.14in">If the infrastructure around
warfarin services is unable to maintain patient safety whilst on
warfarin during the COVID-19 pandemic, the patient will be reviewed
again. 
</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">Kind regards</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">Anticoagulation Specialist
Pharmacist</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-bottom: 0.14in">CC: 
</p>
<p style="margin-bottom: 0.14in">PATIENT NAME</p>
<p style="margin-bottom: 0.14in">ADDRESS</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><b>Appendix 7
- </b>
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><b>The
following are the issues to be covered during patient consultation on
behalf of Dr xxx</b></p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Dear Patient,</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Following the
severe Covid 19 restrictions placed on your ability to leave your
residence, we recognise how difficult it may be for you to have
regular INR blood tests to monitor your warfarin treatment.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Unfortunately
there are also fewer blood sampling sites and phlebotomists, so many
patients are finding it harder to have their blood tested safely. 
Please bear in mind that it is not safe to take warfarin without
regular INR blood tests.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">We propose you
can be safely converted to an alternative tablet, from a group of
medicines commonly known as NOACs (also known as DOACs), which will
continue your anticoagulant treatment, without the need for such
regular blood test monitoring.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">NOACs can be
started three days after stopping warfarin.  You will continue to be
anticoagulated while on a NOAC so you must still remain careful to
avoid injury, falling and excess alcohol.  Most patients prefer NOACs
to warfarin as no INR blood testing will be needed. There are no
dietary restrictions or very few other drug interactions when taking
a NOAC - which is a distinct advantage compared to warfarin.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">We have many
years’ experience in prescribing NOACs for our patients, converting
from warfarin.  NOACs are clinically proven to be equally effective
to warfarin in clinical trials.Very few people have allergic
reactions to NOACs but this is a small possibility. Just like
warfarin, you must take the NOAC tablets regularly as prescribed.  
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">There is less
risk of serious bleeding overall while on a NOAC compared to a severe
bleed while on warfarin in population based studies.  One small
drawback however, is that it is not as easy to reverse the effect of
a NOAC, compared to warfarin, in case of a severe bleed.  
</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">After your
first month's supply from the hospital, your GP will take over the
prescribing who will be informed of the switch.  Nearly all GPs are
now experienced in prescribing NOACs and there are many hundreds of
patients in our hospital service now on NOACs.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">We require
your consent to make the switch from Warfarin to a NOAC, but we
strongly recommend that you do this, as long as you have good kidney
function and are less than 100 kg (equivalent to 15 stone, 11 pounds)
body weight.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">This proposal
has been approved by your anticoagulation pharmacists, consultant
haematologists, GP representatives and the commissioners.</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in"><br/>
<br/>

</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Yours
sincerely</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Dr xxx</p>
<p style="margin-right: 0.31in; margin-bottom: 0.14in">Consultant
Haematologist and Clinical Lead for Anticoagulation Service</p>
<p style="margin-bottom: 0.14in"><br/>
<br/>

</p>
<div title="footer">
	<p style="margin-top: 0.06in; margin-bottom: 0in; line-height: 100%">
	<img src="PACC01%20Standard%20Operating%20procedure%20for%20introducing%20prescribing%20and%20supply%20of%20NOACs%20at%20the%20Anticoagulant%20Clinic_html_3d6b5663a502bb90.png" name="Picture 1" align="left" hspace="12" width="757" height="30" border="0"/>
<br/>

	</p>
</div>
</body>
</html>